Banque Cantonale Vaudoise Raises Stake in Zoetis Inc. (NYSE:ZTS)

Banque Cantonale Vaudoise raised its position in Zoetis Inc. (NYSE:ZTS) by 7.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 80,567 shares of the company’s stock after acquiring an additional 5,539 shares during the quarter. Zoetis makes up about 0.6% of Banque Cantonale Vaudoise’s holdings, making the stock its 27th biggest holding. Banque Cantonale Vaudoise’s holdings in Zoetis were worth $13,967,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after buying an additional 414,605 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares during the last quarter. Capital World Investors lifted its position in shares of Zoetis by 0.6% during the 4th quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after buying an additional 57,798 shares during the last quarter. Norges Bank purchased a new stake in shares of Zoetis during the 4th quarter worth approximately $980,646,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after buying an additional 178,303 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $183.49 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock has a market capitalization of $83.13 billion, a P/E ratio of 35.35, a P/E/G ratio of 2.81 and a beta of 0.86. The company’s fifty day moving average is $179.83 and its two-hundred day moving average is $174.54. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the company posted $1.41 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, sell-side analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 price target on shares of Zoetis in a research report on Tuesday, August 27th. HSBC reduced their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.